Recent News

• 02.06.2026 - Scrip Asks… What Does 2026 Hold for Biopharma? Part 4: R&D Innovation
• 02.06.2026 - Targeting Costimulatory Pathways in Kidney Transplant With Eliezer Katz, MD
• 02.06.2026 - 2-Year Phase 1b Tegoprubart Preserves Kidney Function in Transplant Recipients, With Eliezer Katz, MD
• 01.20.2026 - From pig to patient: Pioneering transplants from pigs to humans could mark a turning point for organ replacement.
• 12.29.2025 - New Immunosuppression Option May Ease Islet Cell Transplants
• 12.18.2025 - Tegoprubart vs Tacrolimus May Reduce Toxicities in Kidney Transplant Recipients
• 12.17.2025 - Promising Phase 2 Data for Tegoprubart in KT
• 11.13.2025 - BESTOW: Tegoprubart Showcases Safer Prevention of Kidney Transplant Rejection Over Tacrolimus

Recent Filings

• 01.21.2026 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 01.16.2026 - 4 Statement of changes in beneficial ownership of securities
• 01.16.2026 - 4 Statement of changes in beneficial ownership of securities
• 01.16.2026 - 4 Statement of changes in beneficial ownership of securities
• 01.16.2026 - 4 Statement of changes in beneficial ownership of securities
• 01.16.2026 - 4 Statement of changes in beneficial ownership of securities
• 01.16.2026 - 4 Statement of changes in beneficial ownership of securities
• 01.02.2026 - 8-K Current report
• 11.24.2025 - SCHEDULE 13G Statement of Beneficial Ownership by Certain Investors
• 11.14.2025 - 8-K Current report